It is very uncertain whether dual antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
Antiplatelet agent showed no clear difference in stroke‐related mortality (CT scan or MRI) compared with placebo (low certainty).
Antiplatelet agent showed no clear difference in ipsilateral major or disabling stroke (CT scan or MRI) compared with placebo (low certainty).
Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).
Multiple probably leads to lower stroke compared with fewer antiplatelet agents (moderate certainty).
Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).
Multiple leads to lower ischaemic stroke compared with fewer antiplatelet agents (high certainty).
Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).
Multiple probably leads to lower stroke, myocardial infarction, or vascular death compared with fewer antiplatelet agents (moderate certainty).
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
NOAC (rivaroxaban) probably leads to higher strokea compared with standard‐dose VKA (moderate certainty).